Healthcare / Health Information ServicesLSE
$2.75
+0.25 (+10.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-3748.00 · quality 48.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
14/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$17M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-288.2%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.22x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-4.0M · FCF $-867924.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-4.0M | $-4.0M | $-13587.00 | $-13821.00 | $-55523.00 |
| EBITDA | $-2.2M | $-2.2M | $-13359.00 | $-13593.00 | $-35623.00 |
| EPS | — | — | -0.00 | -0.00 | -0.00 |
| Balance Sheet | |||||
| Debt/Equity | — | — | -0.74 | -1.21 | — |
| Current Ratio | 2.71 | 2.71 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-867924.00 | $-867924.00 | $-3748.00 | $-526.00 | $-48923.00 |
| Returns | |||||
| ROE | -288.2% | -288.2% | 113.4% | 256.2% | -658.9% |
| Valuation | |||||
| P/B | 817.99 | 817.99 | — | — | — |
| Growth & Yield | |||||
| EPS Growth | — | — | 0.0% | 75.4% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-57.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.00 → n/d
Residual
-57.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.